Summary
Medtronic plc (MDT) announced an important regulatory milestone for its consolidated subsidiary, MiniMed Group, Inc. The U.S. Food and Drug Administration (FDA) has granted clearance for the MiniMed Flex™, a next-generation insulin pump. This clearance arrived several months ahead of schedule, enabling an earlier commercial launch for this significant product in the diabetes management market. The development of the MiniMed Flex was partially funded by Blackstone, and under their agreement, Medtronic will incur a one-time charge of $157 million in the fourth quarter of fiscal year 2026, impacting reported EPS by approximately $0.08 per share. This charge relates to future payments to Blackstone based on sales performance during the initial two years post-launch. Additionally, the previously disclosed initial public offering (IPO) of 10% of MiniMed will contribute an additional $0.04 per share dilution to Medtronic shareholders in the fourth quarter of fiscal year 2026. Consequently, Medtronic has revised its non-GAAP EPS guidance for fiscal year 2026 downward to a range of $5.50 to $5.54, from the previous $5.62 to $5.66 range. The company's long-term outlook for fiscal year 2027, projecting high single-digit EPS growth, remains unchanged.
Key Highlights
- 1FDA clearance for MiniMed Flex™ insulin pump received ahead of schedule.
- 2Earlier commercialization expected for the new smartphone-controlled insulin pump.
- 3A one-time charge of $157 million to be recognized in Q4 FY2026 related to MiniMed Flex™ development funding.
- 4This charge is expected to reduce Q4 FY2026 EPS by approximately $0.08 per share.
- 5Additional $0.04 per share dilution in Q4 FY2026 from the MiniMed IPO.
- 6Revised FY2026 non-GAAP EPS guidance to $5.50-$5.54, down from $5.62-$5.66.
- 7FY2027 EPS growth guidance of high single digits remains unchanged.